Biolife Solutions Inc Stock Price, News & Analysis

BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, has provided updated dial-in information for their earnings call scheduled for today at 4:30pm ET. U.S. participants can dial 1-833-630-0431, while international callers should use 1-412-317-1808.

BioLife Solutions specializes in providing solutions that maintain the health and function of biological materials throughout the collection, development, manufacturing, and distribution processes, supporting the commercialization of new therapies in the CGT market.

BioLife Solutions (NASDAQ: BLFS) reported strong Q1 2025 financial results, with total revenue reaching $23.9 million, up 30% year-over-year. Cell Processing revenue grew 33% to $21.6 million. The company achieved a GAAP gross margin of 63% and reported a reduced GAAP net loss of $0.4 million, with adjusted EBITDA of $5.7 million (24% of revenue). BioLife's biopreservation media is now embedded in 17 commercial cell and gene therapies, with 10 additional approvals expected in the next 12 months. The company completed the acquisition of PanTHERA CryoSolutions in April 2025. BioLife affirmed its 2025 revenue guidance of $95.5-99.0 million, representing 16-20% growth. The company maintains a strong financial position with $107.6 million in cash and marketable securities.

BioLife Solutions, a key player in the cell and gene therapy (CGT) market, has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company, which specializes in bioproduction products and services, will release its Q1 2025 results after market close on Thursday, May 8, 2025.

The company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) on the same day. Management will present the financial results and provide a business update. Investors and interested parties can access the webcast through the company's Investor Relations page or join via phone using the toll-free numbers: 1-877-344-7529 (domestic) or 1-412-317-0088 (international).

A replay of the webcast will be available approximately two hours after the call and will remain accessible on the investor relations website for 90 days.

BioLife Solutions (NASDAQ: BLFS) has acquired PanTHERA CryoSolutions, strengthening its position in the cell and gene therapy (CGT) market. The acquisition focuses on PanTHERA's proprietary Ice Recrystallization Inhibitor (IRI) technology for cryopreservation solutions.

The transaction involves $9.3 million in cash and 241,355 BLFS shares for the remaining 90% ownership, with potential additional payments of up to $7.2 million in stock based on milestone achievements over three years. This marks BioLife's second acquisition from its Bioproduction Innovation Accelerator program.

PanTHERA's next-generation formulations, expected to launch within 18 months, aim to provide superior cryopreservation outcomes, reduce DMSO concentrations, and decrease liquid nitrogen requirements in cold chain logistics and storage.

BioLife Solutions (NASDAQ: BLFS), a leading supplier of bioproduction tools for the cell and gene therapy market, has appointed Cathy Coste to its board of directors, expanding the board to seven members. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who remains a director and committee member.

Coste brings over 40 years of senior executive experience, including 30+ years at Deloitte where she served as a senior partner and life sciences industry executive leader. She has worked with more than two dozen life sciences companies and currently serves as audit committee chair for Biomerica, Minerva Surgical, and Renalytix plc.

The appointment comes as BioLife completes its transition to a pure-play enabler of cell and gene therapies, positioning the company for revenue growth and sustained profitability.

BioLife Solutions (BLFS) reported strong Q4 and full-year 2024 results, with notable growth in its Cell Processing segment. Q4 total revenue reached $22.7 million, up 31% year-over-year, driven by Cell Processing revenue of $20.3 million, representing a 37% increase.

The company achieved a GAAP gross margin of 60% and adjusted EBITDA of $4.0 million (18% of revenue) in Q4. Full-year 2024 revenue totaled $82.3 million, an 8% increase from 2023. The company strengthened its financial position by divesting non-core businesses, including SciSafe and CBS, resulting in a cash position exceeding $100 million.

Looking ahead, BioLife projects 2025 revenue guidance of $95.5-99.0 million, representing 16-20% growth. The Cell Processing platform is expected to grow 18-21% to $86.5-89.0 million. The company's biopreservation media is now embedded in 17 approved cell and gene therapies, with 8 additional approvals anticipated in the next 12 months.

BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, has scheduled its fourth quarter and full year 2024 financial results release for March 3, 2025, before market open.

The company will host a conference call and webcast at 8:00am ET (5:00am PT) on the same day, where management will present financial results and provide a business update. Investors can access the webcast through BioLife's website or join via phone using the toll-free number 1-833-630-0431 (international: 1-412-317-1808). A replay will be available approximately two hours after the call and remain accessible for 90 days on the investor relations website.

BioLife Solutions (NASDAQ: BLFS) reported preliminary Q4 2024 unaudited revenue from continuing operations of $22.7 million, up 31% from Q4 2023. The company's Cell Processing platform revenue reached $20.3 million in Q4, marking a 37% year-over-year increase and 7% sequential growth.

For full-year 2024, revenue from continuing operations totaled $82.3 million, an 8% increase from 2023. Cell Processing platform revenue grew 12% to $73.5 million, exceeding the high end of previously raised guidance. However, Evo and Thaw platform revenue decreased 14% to $8.7 million.

The company completed strategic divestitures in 2024, selling its freezer business (Global Cooling and Arctic Solutions) and storage business (SciSafe), streamlining operations to focus on the cell and gene therapy market. Including SciSafe's discontinued operations revenue of $18.44 million, total preliminary unaudited revenues reached $100.69 million for 2024.

BioLife Solutions (BLFS) has appointed Tony J. Hunt, Executive Chairman of Repligen , to its board of directors effective January 2, 2025, expanding the board to six members. Hunt brings extensive experience in bioprocessing innovation and leadership, having served as Repligen's CEO for nine years before becoming Executive Chairman in September 2024. His prior roles include President of Bioproduction at Life Technologies and Senior Director of Pharma Programs at Applied Biosystems. BioLife Solutions, a leading supplier of cell processing tools for the cell and gene therapy market, aims to leverage Hunt's expertise to strengthen its position in CGT bioprocessing solutions.